Share Price and Basic Stock Data

Last Updated: November 21, 2024, 8:32 pm

Market Cap	431 Cr.
Current Price	19.0
High / Low	29.0/13.2
Stock P/E	24.9
Book Value	7.68
Dividend Yield	0.00 %
ROCE	14.4 %
ROE	10.4 %
Face Value	1.00
PEG Ratio	0.88

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Gennex Laboratories Ltd

Competitors of Gennex Laboratories Ltd

Stock Name	Market Cap	Current Price	High / Low	Stock P/E	Book Value	Dividend Yield	ROCE	ROE	Face Value
Gujarat Themis Biosyn Ltd	3,465 Cr.	318	390/108	65.7	20.5	0.21 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	59.8 Cr.	80.6	94.9/25.8	22.9	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	28.0 Cr.	19.1	19.5/8.35	36.3	6.64	0.00 %	4.06 %	3.33 %	10.0
Godavari Drugs Ltd	85.5 Cr.	114	155/87.0	12.8	55.4	0.00 %	12.7 %	15.5 %	10.0
Glenmark Life Sciences Ltd	13,221 Cr.	1,080	1,335/620	31.2	207	2.08 %	28.1 %	21.1 %	2.00
Industry Average	19,460.76 Cr	1,177.05		54.20	184.88	0.33%	16.40%	16.92%	6.61

All Competitor Stocks of Gennex Laboratories Ltd

Quarterly Result

Month	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Sales	10.40	14.29	16.69	21.22	14.51	19.62	14.63	20.80	16.52	18.18	21.39	35.52	30.79
Expenses	8.75	12.34	15.36	19.39	13.06	17.76	12.81	17.28	11.42	12.41	16.59	29.26	24.10
Operating Profit	1.65	1.95	1.33	1.83	1.45	1.86	1.82	3.52	5.10	5.77	4.80	6.26	6.69
OPM %	15.87%	13.65%	7.97%	8.62%	9.99%	9.48%	12.44%	16.92%	30.87%	31.74%	22.44%	17.62%	21.73%
Other Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest	0.15	0.24	0.14	0.20	0.26	0.10	0.19	0.63	0.73	0.78	0.83	0.73	0.73
Depreciation	0.20	0.20	0.19	0.34	0.18	0.36	0.18	0.37	0.65	1.03	0.45	0.23	0.45
Profit before tax	1.30	1.51	1.00	1.29	1.01	1.40	1.45	2.52	3.72	3.96	3.52	5.30	5.51
Tax %	26.92%	26.49%	21.00%	16.28%	24.75%	25.00%	24.83%	19.05%	23.39%	22.47%	21.31%	15.28%	15.43%
Net Profit	0.95	1.11	0.79	1.07	0.75	1.05	1.08	2.04	2.85	3.07	2.76	4.50	4.66
EPS in Rs	0.05	0.06	0.04	0.06	0.04	0.06	0.07	0.12	0.16	0.17	0.16	0.20	0.20

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: September 23, 2024, 2:23 pm

Month	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	42	44	56	56	60	61	66	87	106
Expenses	37	42	52	52	53	56	61	70	82
Operating Profit	5	2	4	3	7	5	5	17	24
OPM %	11%	5%	7%	6%	11%	9%	7%	20%	22%
Other Income	0	1	1	1	0	1	4	5	0
Interest	1	1	1	1	1	1	1	3	3
Depreciation	1	1	1	1	1	1	1	2	2
Profit before tax	3	1	3	3	5	5	6	16	18
Tax %	13%	42%	26%	27%	20%	23%	23%	20%
Net Profit	3	1	2	2	4	4	5	13	15
EPS in Rs	0.14	0.04	0.12	0.10	0.21	0.21	0.28	0.58	0.73
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	-66.67%	100.00%	0.00%	100.00%	0.00%	25.00%	160.00%
Change in YoY Net Profit Growth (%)	0.00%	166.67%	-100.00%	100.00%	-100.00%	25.00%	135.00%

Gennex Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2017-2018 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	9%
3 Years:	13%
TTM:	73%

Compounded Profit Growth
10 Years:	%
5 Years:	42%
3 Years:	43%
TTM:	91%

Stock Price CAGR
10 Years:	16%
5 Years:	47%
3 Years:	42%
1 Year:	18%

Return on Equity
10 Years:	%
5 Years:	9%
3 Years:	10%
Last Year:	10%

Last Updated: Unknown

Balance Sheet

Last Updated: October 15, 2024, 1:34 pm

Month	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Equity Capital	13	13	13	13	13	13	18	23
Reserves	18	19	21	23	27	31	62	142
Borrowings	4	2	5	5	7	10	1	6
Other Liabilities	14	16	13	16	12	14	51	60
Total Liabilities	49	50	52	57	59	68	132	230
Fixed Assets	16	16	16	15	14	14	74	56
CWIP	0	0	0	0	0	0	0	2
Investments	7	7	7	7	7	7	0	0
Other Assets	26	28	29	35	38	48	59	172
Total Assets	49	50	52	57	59	68	132	230

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	-0	3	2	-2	-1	12	24	-47
Cash from Investing Activity +	-1	-1	-1	-0	-0	-2	-38	19
Cash from Financing Activity +	1	-2	1	-0	2	-2	21	74
Net Cash Flow	-0	0	2	-2	0	8	6	46

Free Cash Flow

Month	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	1.00	0.00	-1.00	-2.00	0.00	-5.00	4.00	11.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	90	87	68	41	55	67	52	75
Inventory Days	43	31	57	78	50	72	139	184
Days Payable	139	161	88	86	59	72	63	111
Cash Conversion Cycle	-7	-43	38	34	46	67	129	148
Working Capital Days	106	93	86	119	153	148	29	279
ROCE %		6%	11%	8%	14%	12%	11%	14%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters	22.05%	22.05%	22.05%	23.38%	23.38%	23.38%	23.38%	23.61%	23.61%	18.41%	18.41%	18.41%
Public	77.95%	77.95%	77.95%	76.63%	76.62%	76.62%	76.62%	76.39%	76.39%	81.58%	81.57%	81.59%
No. of Shareholders	50,052	56,689	57,877	59,172	58,248	55,609	52,981	50,988	69,723	83,996	87,820	90,236

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	1.00	1.00	1.00	1.00	1.00
Basic EPS (Rs.)	0.67	0.42	0.33	0.32	0.15
Diluted EPS (Rs.)	0.61	0.42	0.33	0.32	0.15
Cash EPS (Rs.)	0.68	0.32	0.37	0.38	0.22
Book Value[Excl.RevalReserv]/Share (Rs.)	7.76	4.80	3.46	3.14	2.82
Book Value[Incl.RevalReserv]/Share (Rs.)	7.76	4.80	3.46	3.14	2.82
Revenue From Operations / Share (Rs.)	3.81	3.64	4.84	4.72	4.40
PBDIT / Share (Rs.)	0.96	0.47	0.53	0.55	0.33
PBIT / Share (Rs.)	0.86	0.42	0.47	0.48	0.25
PBT / Share (Rs.)	0.72	0.35	0.40	0.40	0.20
Net Profit / Share (Rs.)	0.57	0.27	0.31	0.31	0.14
NP After MI And SOA / Share (Rs.)	0.57	0.27	0.31	0.31	0.14
PBDIT Margin (%)	25.29	13.17	11.04	11.83	7.54
PBIT Margin (%)	22.56	11.77	9.75	10.35	5.74
PBT Margin (%)	19.01	9.71	8.32	8.48	4.58
Net Profit Margin (%)	15.19	7.50	6.40	6.76	3.33
NP After MI And SOA Margin (%)	15.19	7.50	6.40	6.76	3.33
Return on Networth / Equity (%)	7.73	6.12	8.95	10.16	5.20
Return on Capital Employeed (%)	10.31	7.51	13.62	15.49	8.84
Return On Assets (%)	5.72	3.71	5.76	6.85	3.25
Total Debt / Equity (X)	0.03	0.01	0.23	0.18	0.13
Asset Turnover Ratio (%)	0.47	0.65	0.96	1.03	1.02
Current Ratio (X)	4.01	1.65	1.95	1.98	1.68
Quick Ratio (X)	3.39	1.12	1.63	1.71	1.32
Inventory Turnover Ratio (X)	2.83	4.00	6.27	5.49	5.50
Interest Coverage Ratio (X)	7.13	6.39	7.70	9.49	5.57
Interest Coverage Ratio (Post Tax) (X)	5.28	4.63	5.47	6.93	3.32
Enterprise Value (Cr.)	310.20	93.24	97.07	55.76	27.60
EV / Net Operating Revenue (X)	3.58	1.42	1.59	0.93	0.49
EV / EBITDA (X)	14.14	10.78	14.36	7.90	6.57
MarketCap / Net Operating Revenue (X)	4.14	1.54	1.56	0.82	0.42
Price / BV (X)	2.11	1.26	2.17	1.25	0.65
Price / Net Operating Revenue (X)	4.14	1.54	1.56	0.82	0.42
EarningsYield	0.03	0.04	0.04	0.08	0.07

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Gennex Laboratories Ltd as of November 22, 2024 is: 20.29

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 22, 2024, Gennex Laboratories Ltd is Undervalued by 6.79% compared to the current share price 19.00

Intrinsic Value of Gennex Laboratories Ltd as of November 22, 2024 is: 26.03

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 22, 2024, Gennex Laboratories Ltd is Undervalued by 37.00% compared to the current share price 19.00

Last 5 Year EPS CAGR: 28.30%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock is trading at a low valuation with an average P/B ratio of 0.50 and average Dividend Yield of 12.03%. The company has higher reserves (42.88 cr) compared to borrowings (5.00 cr), indicating strong financial stability. The company has shown consistent growth in sales (64.22 cr) and profit (6.67 cr) over the years.	The stock has a low average ROCE of 9.50%, which may not be favorable. The stock has a high average Working Capital Days of 126.63, which may not be favorable. The stock has a high average Cash Conversion Cycle of 51.50, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gennex Laboratories Ltd:
1. Net Profit Margin: 15.19%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 10.31% (Industry Average ROCE: 16.25%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 7.73% (Industry Average ROE: 16.45%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 5.28
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 3.39
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 24.9 (Industry average Stock P/E: 43.76)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.03
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Gennex Laboratories Ltd. is a Public Limited Listed company incorporated on 29/03/1990 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L24230TG1990PLC011168 and registration number is 011168. Currently company belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 61.21 Cr. and Equity Capital is Rs. 12.65 Cr. for the Year ended 31/03/2022.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Sy. No.133, Sangareddy Dist. Telangana 502325	info@gennexlab.com http://www.gennexlab.com

Management
Name	Position Held
Mr. Arihant Baid	Chairman & Managing Director
Mr. T M Gopalakrishnan	Whole Time Director
Mr. A R R Pantulu	Non Executive Director
Mr. Y Ravinder Reddy	Independent Director
Mr. A S Nageswar Rao	Independent Director
Ms. Sadhana Bhansali	Independent Woman Director

FAQ

What is the latest intrinsic value of Gennex Laboratories Ltd?

The latest intrinsic value of Gennex Laboratories Ltd as on 22 November 2024 is ₹20.29, which is 6.79% higher than the current market price of ₹19.00.

What is the Market Cap of Gennex Laboratories Ltd?

The Market Cap of Gennex Laboratories Ltd is 431 Cr..

What is the current Stock Price of Gennex Laboratories Ltd as on 22 November 2024?

The current stock price of Gennex Laboratories Ltd as on 22 November 2024 is ₹19.0.

What is the High / Low of Gennex Laboratories Ltd stocks in FY 2024?

In FY 2024, the High / Low of Gennex Laboratories Ltd stocks is 29.0/13.2.

What is the Stock P/E of Gennex Laboratories Ltd?

The Stock P/E of Gennex Laboratories Ltd is 24.9.

What is the Book Value of Gennex Laboratories Ltd?

The Book Value of Gennex Laboratories Ltd is 7.68.

What is the Dividend Yield of Gennex Laboratories Ltd?

The Dividend Yield of Gennex Laboratories Ltd is 0.00 %.

What is the ROCE of Gennex Laboratories Ltd?

The ROCE of Gennex Laboratories Ltd is 14.4 %.

What is the ROE of Gennex Laboratories Ltd?

The ROE of Gennex Laboratories Ltd is 10.4 %.

What is the Face Value of Gennex Laboratories Ltd?

The Face Value of Gennex Laboratories Ltd is 1.00.